MRNA
Moderna, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Moderna has 7 disclosed suppliers and 5 disclosed customers in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−5.35%
vs ±9.8% implied · ×0.55
shaded = implied · ▲▼ = realized
SentenceThe following table shows customers that made up at least 10% of total revenue in each year presented:
Year Ended December 31,
2025
2024
Moderna, Inc.
22%
28%
basisPSNL FY2025 revenue $70MMRNA FY2025 revenue $1.9B
SentenceOur molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
SentenceFill-and-finish of the vaccine, including the new single-use pre-filled syringes, is completed by Novocol Pharma in Cambridge, Ontario.
MRNA 10-Kaccession 0001682852-26-000033
SentenceIn September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).
SentenceIn addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us.
MRNA 10-Kaccession 0001682852-26-000033
SentenceIn addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us.
MRNA 10-Kaccession 0001682852-26-000033
SentenceIn addition, we have built and manage mRNA manufacturing facilities in the United Kingdom, Canada and Australia. These facilities were fully licensed in 2025, and the government in each of these countries has entered into a multi-year commitment to purchase mRNA products from us.
MRNA 10-Kaccession 0001682852-26-000033
Moderna, Inc.
221.40
Expected move
Inputs8Q avg ±4.0%·×0.58·cheap
straddle ±9.2%
spot 221.72exp Nov 6ATM strike 222.5ATM straddle 23.88IV 97%